CTOs on the Move

QED Therapeutics

www.qedtx.com

 
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

QED Therapeutics raised $65M on 01/30/2018

Similar Companies

EYELA Tokyo Rikakikai Co

EYELA Tokyo Rikakikai Co is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Combimatrix Molecular Diagnostics

Combimatrix Molecular Diagnostics is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Prosetta

Prosetta Biosciences, Inc. is an 11-year old biotechnology company developing novel small-molecule antiviral therapeutics based on over 25 years of basic research on the Cell-Free Protein Synthesizing Systems (CFPSS) by scientists at the University of California, San Francisco and the University of Washington, Seattle. The incorporation of the CFPSS in our drug discovery platform, has lead to the identification of small molecules which disrupt or alter the key protein-protein interactions involved with the assembly of viral capsids (the protein shell that protects the DNA or RNA genome of a virus). Prosetta has successfully produced highly potent compounds which display activity against multiple strains of many viral families including lead series of molecules that are effective antiviral agents against Influenza, HIV and HCV.

MedXcel

MedXcel is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Atmofizer

The world’s most innovative and effective clean air technology against harmful ultra fine particles incl. COVID-19. Developed in Germany, assembled in the US.